RxDoctor Payments Data

Tamara Bailey

Family · Washington, MONPI 1184122327

Payments from drug & device makers

$5,293in general payments, 2019–2025

Across 340 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$555
  • Lilly USA, LLC$447
  • AbbVie$409
  • Novo Nordisk$344
  • Otsuka America Pharmaceutical, Inc.$330
  • Abbott$259
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,293 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$38,064
Medicare patients
267
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$16,064
FarxigaDapagliflozin Propanediol12$9,671
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,086
PaxlovidNirmatrelvir/Ritonavir18$2,783
SymbicortBudesonide/Formoterol Fumarate12$2,584
Doxycycline Hyclate121$932
CefuroximeCefuroxime Axetil73$738
Cefdinir53$699
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst44$539
Amlodipine Besylate77$428
Albuterol Sulfate HfaAlbuterol Sulfate27$395
Duloxetine Hcl18$354
Methylprednisolone56$344
Oseltamivir Phosphate16$324
Omeprazole25$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$344$16,06416 claims
AstraZenecaFarxiga, Symbicort$258$12,25524 claims
GSKTrelegy Ellipta$222$9,08614 claims
PfizerPaxlovid$106$2,78318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.

Other family in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →